Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
The evidence base consists primarily of preclinical studies in animal models, with limited clinical data in humans
In occlusion/occlusion-like syndromes affecting both periphery and brain (portal hypertension, caval hypertension, intracranial hypertension), BPC-157 simultaneously normalized blood pressure disturbances, healed gastrointestinal and liver lesions, minimized brain lesions and hemorrhage, prevented thrombosis, and preserved neurological function
This is crucial to achieving the best possible outcome, allowing them to make adjustments to your treatment plan as needed
Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS
Red flags include: no third-party COA available on request, COA issued by the same company selling the product, no mass spec data, dose listed only as a proprietary blend, and price far below market rate for verified peptide raw material
As a research peptide, BPC-157 belongs to the class of gastric pentadecapeptides
US$ 22.78
US$ 21.52
US$ 22.04
US$ 23.79
